UroGen Pharma Announces September 2020 Conference Schedule
-
H.C. Wainwright 22nd AnnualGlobal Investment Conference -
Wednesday, September 16 th -
10:00AM Eastern Time
-
-
Cantor Virtual Global Healthcare Conference -
Thursday, September 17 th -
4:00PM Eastern Time
-
A live audio webcast of each event will be available on the Investors section of UroGen's website, www.urogen.com. A replay of each webcast will be available on the website for approximately two weeks.
About
UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s approved product, Jelmyto® (mitomycin) for pyelocalyceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer, respectively. UroGen is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20200910005163/en/
INVESTOR CONTACT:
Head of Investor Relations
Sara.Sherman@urogen.com
609-467-4975
MEDIA CONTACT:
Senior Director, Communications
Eric.VanZanten@urogen.com
610-529-6219
Source: